EP2864340A1 - Peptide-silica hybrid materials - Google Patents
Peptide-silica hybrid materialsInfo
- Publication number
- EP2864340A1 EP2864340A1 EP13730896.1A EP13730896A EP2864340A1 EP 2864340 A1 EP2864340 A1 EP 2864340A1 EP 13730896 A EP13730896 A EP 13730896A EP 2864340 A1 EP2864340 A1 EP 2864340A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- peptide
- group
- fragment
- strand
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 title claims abstract description 85
- 239000000463 material Substances 0.000 title claims abstract description 82
- 239000000377 silicon dioxide Substances 0.000 title claims abstract description 42
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 42
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 42
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 163
- 150000001413 amino acids Chemical class 0.000 claims description 55
- 239000000863 peptide conjugate Substances 0.000 claims description 48
- 239000012634 fragment Substances 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 40
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 39
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 36
- 102000007079 Peptide Fragments Human genes 0.000 claims description 32
- 108010033276 Peptide Fragments Proteins 0.000 claims description 32
- 230000000845 anti-microbial effect Effects 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 31
- 230000003115 biocidal effect Effects 0.000 claims description 29
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 27
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 27
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 27
- -1 aliphatic hydrocarbon radical Chemical class 0.000 claims description 26
- 125000004432 carbon atom Chemical group C* 0.000 claims description 26
- 229920001577 copolymer Polymers 0.000 claims description 26
- 229940121375 antifungal agent Drugs 0.000 claims description 24
- 230000000843 anti-fungal effect Effects 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 21
- 125000006850 spacer group Chemical group 0.000 claims description 20
- 239000003242 anti bacterial agent Substances 0.000 claims description 19
- 239000004599 antimicrobial Substances 0.000 claims description 19
- 125000006239 protecting group Chemical group 0.000 claims description 19
- 239000002105 nanoparticle Substances 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 18
- 125000003118 aryl group Chemical group 0.000 claims description 17
- 125000004122 cyclic group Chemical group 0.000 claims description 17
- 150000003254 radicals Chemical class 0.000 claims description 17
- 239000003054 catalyst Substances 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 16
- 125000005843 halogen group Chemical group 0.000 claims description 15
- 229920006395 saturated elastomer Polymers 0.000 claims description 14
- 238000010647 peptide synthesis reaction Methods 0.000 claims description 13
- 239000011521 glass Substances 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 11
- 150000001412 amines Chemical group 0.000 claims description 10
- 230000001413 cellular effect Effects 0.000 claims description 10
- 238000009833 condensation Methods 0.000 claims description 10
- 230000005494 condensation Effects 0.000 claims description 10
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 9
- 238000006555 catalytic reaction Methods 0.000 claims description 9
- 229910052731 fluorine Inorganic materials 0.000 claims description 9
- 238000007306 functionalization reaction Methods 0.000 claims description 9
- 125000001931 aliphatic group Chemical group 0.000 claims description 8
- 238000006460 hydrolysis reaction Methods 0.000 claims description 8
- 238000000926 separation method Methods 0.000 claims description 8
- 230000003213 activating effect Effects 0.000 claims description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 7
- 238000010511 deprotection reaction Methods 0.000 claims description 7
- 230000007062 hydrolysis Effects 0.000 claims description 7
- 239000003446 ligand Substances 0.000 claims description 7
- 239000011159 matrix material Substances 0.000 claims description 7
- 229910044991 metal oxide Inorganic materials 0.000 claims description 7
- 150000004706 metal oxides Chemical class 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 7
- 208000027418 Wounds and injury Diseases 0.000 claims description 6
- 238000004587 chromatography analysis Methods 0.000 claims description 6
- 239000002532 enzyme inhibitor Substances 0.000 claims description 6
- 229940125532 enzyme inhibitor Drugs 0.000 claims description 6
- 125000000524 functional group Chemical group 0.000 claims description 6
- 230000001737 promoting effect Effects 0.000 claims description 6
- 206010052428 Wound Diseases 0.000 claims description 5
- 125000000732 arylene group Chemical group 0.000 claims description 5
- 239000011324 bead Substances 0.000 claims description 5
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 claims description 4
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 239000002537 cosmetic Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 238000011065 in-situ storage Methods 0.000 claims description 4
- 239000002243 precursor Substances 0.000 claims description 4
- KRTGJZMJJVEKRX-UHFFFAOYSA-N 2-phenylethan-1-yl Chemical compound [CH2]CC1=CC=CC=C1 KRTGJZMJJVEKRX-UHFFFAOYSA-N 0.000 claims description 3
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 239000000562 conjugate Substances 0.000 claims description 3
- 229920001296 polysiloxane Polymers 0.000 claims description 3
- 150000001263 acyl chlorides Chemical class 0.000 claims description 2
- 230000000840 anti-viral effect Effects 0.000 claims description 2
- 150000001540 azides Chemical class 0.000 claims description 2
- 210000004900 c-terminal fragment Anatomy 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 239000012948 isocyanate Substances 0.000 claims description 2
- 150000002513 isocyanates Chemical class 0.000 claims description 2
- 210000004898 n-terminal fragment Anatomy 0.000 claims description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical group O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims description 2
- 229910008326 Si-Y Inorganic materials 0.000 claims 1
- 229910006773 Si—Y Inorganic materials 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- 229910000077 silane Inorganic materials 0.000 abstract description 4
- 229940024606 amino acid Drugs 0.000 description 56
- 235000001014 amino acid Nutrition 0.000 description 54
- 102000004196 processed proteins & peptides Human genes 0.000 description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 23
- 239000000243 solution Substances 0.000 description 20
- 125000000217 alkyl group Chemical group 0.000 description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 14
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 12
- 238000006116 polymerization reaction Methods 0.000 description 12
- 229920005989 resin Polymers 0.000 description 12
- 239000011347 resin Substances 0.000 description 12
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
- 150000001338 aliphatic hydrocarbons Chemical group 0.000 description 10
- 230000012010 growth Effects 0.000 description 10
- 239000011148 porous material Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 229920000642 polymer Polymers 0.000 description 9
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- FRGPKMWIYVTFIQ-UHFFFAOYSA-N triethoxy(3-isocyanatopropyl)silane Chemical compound CCO[Si](OCC)(OCC)CCCN=C=O FRGPKMWIYVTFIQ-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 7
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 229910052801 chlorine Inorganic materials 0.000 description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
- 239000000178 monomer Substances 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 239000013638 trimer Substances 0.000 description 6
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 108010069514 Cyclic Peptides Proteins 0.000 description 5
- 102000001189 Cyclic Peptides Human genes 0.000 description 5
- 241000233866 Fungi Species 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- 235000004279 alanine Nutrition 0.000 description 5
- 239000003429 antifungal agent Substances 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 4
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 4
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 4
- 150000001336 alkenes Chemical class 0.000 description 4
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000007822 coupling agent Substances 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- 229910052710 silicon Inorganic materials 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 3
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 150000001345 alkine derivatives Chemical class 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 238000004873 anchoring Methods 0.000 description 3
- 230000000181 anti-adherent effect Effects 0.000 description 3
- 230000003214 anti-biofilm Effects 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 3
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 125000005594 diketone group Chemical group 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 150000002825 nitriles Chemical class 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000000816 peptidomimetic Substances 0.000 description 3
- 150000003147 proline derivatives Chemical class 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 108010004034 stable plasma protein solution Proteins 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- GVIXTVCDNCXXSH-AWEZNQCLSA-N (2s)-2-amino-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]pentanoic acid Chemical compound OC(=O)[C@@H](N)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C GVIXTVCDNCXXSH-AWEZNQCLSA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical group NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 229920002415 Pluronic P-123 Polymers 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- WNNNWFKQCKFSDK-UHFFFAOYSA-N allylglycine Chemical compound OC(=O)C(N)CC=C WNNNWFKQCKFSDK-UHFFFAOYSA-N 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- KDKYADYSIPSCCQ-UHFFFAOYSA-N but-1-yne Chemical compound CCC#C KDKYADYSIPSCCQ-UHFFFAOYSA-N 0.000 description 2
- 229910052792 caesium Inorganic materials 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007334 copolymerization reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- POMXNGQIMBZZOK-UHFFFAOYSA-N dichloro-(3-isocyanatopropyl)-methylsilane Chemical compound C[Si](Cl)(Cl)CCCN=C=O POMXNGQIMBZZOK-UHFFFAOYSA-N 0.000 description 2
- UWGIJJRGSGDBFJ-UHFFFAOYSA-N dichloromethylsilane Chemical group [SiH3]C(Cl)Cl UWGIJJRGSGDBFJ-UHFFFAOYSA-N 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- XNLICIUVMPYHGG-UHFFFAOYSA-N pentan-2-one Chemical compound CCCC(C)=O XNLICIUVMPYHGG-UHFFFAOYSA-N 0.000 description 2
- 238000006068 polycondensation reaction Methods 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 125000005369 trialkoxysilyl group Chemical group 0.000 description 2
- 229920000428 triblock copolymer Polymers 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 235000014393 valine Nutrition 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 150000003679 valine derivatives Chemical class 0.000 description 2
- USQHEVWOPJDAAX-PHDIDXHHSA-N (1r,2r)-2-aminocyclohexane-1-carboxylic acid Chemical compound N[C@@H]1CCCC[C@H]1C(O)=O USQHEVWOPJDAAX-PHDIDXHHSA-N 0.000 description 1
- JWYOAMOZLZXDER-RFZPGFLSSA-N (1r,2r)-2-azaniumylcyclopentane-1-carboxylate Chemical compound N[C@@H]1CCC[C@H]1C(O)=O JWYOAMOZLZXDER-RFZPGFLSSA-N 0.000 description 1
- USQHEVWOPJDAAX-RITPCOANSA-N (1r,2s)-2-aminocyclohexane-1-carboxylic acid Chemical compound N[C@H]1CCCC[C@H]1C(O)=O USQHEVWOPJDAAX-RITPCOANSA-N 0.000 description 1
- JWYOAMOZLZXDER-UHNVWZDZSA-N (1r,2s)-2-azaniumylcyclopentane-1-carboxylate Chemical compound N[C@H]1CCC[C@H]1C(O)=O JWYOAMOZLZXDER-UHNVWZDZSA-N 0.000 description 1
- USQHEVWOPJDAAX-NTSWFWBYSA-N (1s,2r)-2-azaniumylcyclohexane-1-carboxylate Chemical compound N[C@@H]1CCCC[C@@H]1C(O)=O USQHEVWOPJDAAX-NTSWFWBYSA-N 0.000 description 1
- USQHEVWOPJDAAX-WDSKDSINSA-N (1s,2s)-2-azaniumylcyclohexane-1-carboxylate Chemical compound N[C@H]1CCCC[C@@H]1C(O)=O USQHEVWOPJDAAX-WDSKDSINSA-N 0.000 description 1
- JNTMAZFVYNDPLB-PEDHHIEDSA-N (2S,3S)-2-[[[(2S)-1-[(2S,3S)-2-amino-3-methyl-1-oxopentyl]-2-pyrrolidinyl]-oxomethyl]amino]-3-methylpentanoic acid Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JNTMAZFVYNDPLB-PEDHHIEDSA-N 0.000 description 1
- XRJDXNUDLMKKQI-GFCCVEGCSA-N (2r)-2-[(3,4-difluorophenyl)methyl]pyrrolidine-2-carboxylic acid Chemical compound C=1C=C(F)C(F)=CC=1C[C@@]1(C(=O)O)CCCN1 XRJDXNUDLMKKQI-GFCCVEGCSA-N 0.000 description 1
- FQRURPFZTFUXEZ-MRVPVSSYSA-N (2s)-2,3,3,3-tetrafluoro-2-(n-fluoroanilino)propanoic acid Chemical compound OC(=O)[C@](F)(C(F)(F)F)N(F)C1=CC=CC=C1 FQRURPFZTFUXEZ-MRVPVSSYSA-N 0.000 description 1
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
- RUGBRAKTJNIFOM-PUOGSPQQSA-N (2s)-2-(difluoroamino)-2,3,3,4-tetrafluorohexanoic acid Chemical compound CCC(F)C(F)(F)[C@](F)(N(F)F)C(O)=O RUGBRAKTJNIFOM-PUOGSPQQSA-N 0.000 description 1
- IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 description 1
- SAAQPSNNIOGFSQ-LURJTMIESA-N (2s)-2-(pyridin-4-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=NC=C1 SAAQPSNNIOGFSQ-LURJTMIESA-N 0.000 description 1
- WBZIGVCQRXJYQD-YFKPBYRVSA-N (2s)-2-amino-3-(1,3-thiazol-4-yl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CSC=N1 WBZIGVCQRXJYQD-YFKPBYRVSA-N 0.000 description 1
- RFOVYDPRGDZBLJ-QMMMGPOBSA-N (2s)-2-amino-3-(2,6-difluorophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=C(F)C=CC=C1F RFOVYDPRGDZBLJ-QMMMGPOBSA-N 0.000 description 1
- PRAWYXDDKCVZTL-QMMMGPOBSA-N (2s)-2-amino-3-(3,4-difluorophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(F)C(F)=C1 PRAWYXDDKCVZTL-QMMMGPOBSA-N 0.000 description 1
- PDRJLZDUOULRHE-ZETCQYMHSA-N (2s)-2-amino-3-pyridin-2-ylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=N1 PDRJLZDUOULRHE-ZETCQYMHSA-N 0.000 description 1
- RDQOEQUFZYLLRT-VIFPVBQESA-N (2s)-2-azaniumyl-2-benzyl-3,3,3-trifluoropropanoate Chemical compound OC(=O)[C@@](C(F)(F)F)(N)CC1=CC=CC=C1 RDQOEQUFZYLLRT-VIFPVBQESA-N 0.000 description 1
- KSUXKFDPNKLPHX-ZETCQYMHSA-N (2s)-2-azaniumyl-3-(2,3-difluorophenyl)propanoate Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC=CC(F)=C1F KSUXKFDPNKLPHX-ZETCQYMHSA-N 0.000 description 1
- MNZLMQYCEWHPPS-REOHCLBHSA-N (2s)-2-azaniumyl-5,5,5-trifluoro-4-(trifluoromethyl)pentanoate Chemical compound OC(=O)[C@@H](N)CC(C(F)(F)F)C(F)(F)F MNZLMQYCEWHPPS-REOHCLBHSA-N 0.000 description 1
- SJTPYAOZAPSOLO-REOHCLBHSA-N (2s)-2-hydrazinyl-3-hydroxypropanoic acid Chemical compound NN[C@@H](CO)C(O)=O SJTPYAOZAPSOLO-REOHCLBHSA-N 0.000 description 1
- ZPBIYZHGBPBZCK-VKHMYHEASA-N (2s)-4,4-difluoropyrrolidin-1-ium-2-carboxylate Chemical compound OC(=O)[C@@H]1CC(F)(F)CN1 ZPBIYZHGBPBZCK-VKHMYHEASA-N 0.000 description 1
- ZIWHMENIDGOELV-BKLSDQPFSA-N (2s)-4-fluoropyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CC(F)CN1 ZIWHMENIDGOELV-BKLSDQPFSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- SHINASQYHDCLEU-DMTCNVIQSA-N (2s,4r)-4-aminopyrrolidine-2-carboxylic acid Chemical compound N[C@H]1CN[C@H](C(O)=O)C1 SHINASQYHDCLEU-DMTCNVIQSA-N 0.000 description 1
- JQVMMZMKXGQVGQ-MNOVXSKESA-N (2s,4r)-4-benzylpyrrolidine-2-carboxylic acid Chemical compound C1N[C@H](C(=O)O)C[C@H]1CC1=CC=CC=C1 JQVMMZMKXGQVGQ-MNOVXSKESA-N 0.000 description 1
- VHWBYQPKMIHOSS-SECBINFHSA-N (4r)-4-amino-5-(4-hydroxyphenyl)pentanoic acid Chemical compound OC(=O)CC[C@@H](N)CC1=CC=C(O)C=C1 VHWBYQPKMIHOSS-SECBINFHSA-N 0.000 description 1
- JPYGFLFUDLRNKX-SCSAIBSYSA-N (4r)-4-amino-5-hydroxypentanoic acid Chemical compound OC[C@H](N)CCC(O)=O JPYGFLFUDLRNKX-SCSAIBSYSA-N 0.000 description 1
- ONTGVUKSHAFZCY-ZCFIWIBFSA-N (4r)-4-aminoheptanethioic s-acid Chemical compound CCC[C@@H](N)CCC(S)=O ONTGVUKSHAFZCY-ZCFIWIBFSA-N 0.000 description 1
- HYYFSIISRIDZPM-ZCFIWIBFSA-N (4r)-4-azaniumyl-5-methylhexanoate Chemical compound CC(C)[C@H](N)CCC(O)=O HYYFSIISRIDZPM-ZCFIWIBFSA-N 0.000 description 1
- URBAOHLJWLYLQE-SNVBAGLBSA-N (4r)-4-azaniumyl-5-phenylpentanoate Chemical compound OC(=O)CC[C@@H](N)CC1=CC=CC=C1 URBAOHLJWLYLQE-SNVBAGLBSA-N 0.000 description 1
- DVEQYBXCFNPUGR-NKWVEPMBSA-N (4r,5s)-4-amino-5-methylheptanoic acid Chemical compound CC[C@H](C)[C@H](N)CCC(O)=O DVEQYBXCFNPUGR-NKWVEPMBSA-N 0.000 description 1
- PJBIRKFNLCOMSB-ZETCQYMHSA-N (4s)-4,8-diaminooctanoic acid Chemical compound NCCCC[C@H](N)CCC(O)=O PJBIRKFNLCOMSB-ZETCQYMHSA-N 0.000 description 1
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- OXFGRWIKQDSSLY-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinolin-2-ium-1-carboxylate Chemical compound C1=CC=C2C(C(=O)O)NCCC2=C1 OXFGRWIKQDSSLY-UHFFFAOYSA-N 0.000 description 1
- FVTVMQPGKVHSEY-UHFFFAOYSA-N 1-AMINOCYCLOBUTANE CARBOXYLIC ACID Chemical compound OC(=O)C1(N)CCC1 FVTVMQPGKVHSEY-UHFFFAOYSA-N 0.000 description 1
- NILQLFBWTXNUOE-UHFFFAOYSA-N 1-aminocyclopentanecarboxylic acid Chemical compound OC(=O)C1(N)CCCC1 NILQLFBWTXNUOE-UHFFFAOYSA-N 0.000 description 1
- PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 description 1
- HTTPGMNPPMMMOP-UHFFFAOYSA-N 1-azaniumyl-2,3-dihydroindene-1-carboxylate Chemical compound C1=CC=C2C(N)(C(O)=O)CCC2=C1 HTTPGMNPPMMMOP-UHFFFAOYSA-N 0.000 description 1
- BLCJBICVQSYOIF-UHFFFAOYSA-N 2,2-diaminobutanoic acid Chemical compound CCC(N)(N)C(O)=O BLCJBICVQSYOIF-UHFFFAOYSA-N 0.000 description 1
- OMGHIGVFLOPEHJ-UHFFFAOYSA-N 2,5-dihydro-1h-pyrrol-1-ium-2-carboxylate Chemical compound OC(=O)C1NCC=C1 OMGHIGVFLOPEHJ-UHFFFAOYSA-N 0.000 description 1
- FSZMHEMPLAVBQZ-QMMMGPOBSA-N 2,5-dihydrophenyl-L-alanine Chemical compound OC(=O)[C@@H](N)CC1=CCC=CC1 FSZMHEMPLAVBQZ-QMMMGPOBSA-N 0.000 description 1
- STWYUDQLBORQDI-UHFFFAOYSA-N 2-(2,4-difluoroanilino)acetic acid Chemical compound OC(=O)CNC1=CC=C(F)C=C1F STWYUDQLBORQDI-UHFFFAOYSA-N 0.000 description 1
- CSEWAUGPAQPMDC-UHFFFAOYSA-N 2-(4-aminophenyl)acetic acid Chemical compound NC1=CC=C(CC(O)=O)C=C1 CSEWAUGPAQPMDC-UHFFFAOYSA-N 0.000 description 1
- WAPLXGPARWRGJO-UHFFFAOYSA-N 2-(4-aminophenyl)butanoic acid Chemical compound CCC(C(O)=O)C1=CC=C(N)C=C1 WAPLXGPARWRGJO-UHFFFAOYSA-N 0.000 description 1
- WOMVICAMAQURRN-UHFFFAOYSA-N 2-(4-aminophenyl)propanoic acid Chemical compound OC(=O)C(C)C1=CC=C(N)C=C1 WOMVICAMAQURRN-UHFFFAOYSA-N 0.000 description 1
- XVDSFSRMHSDHGJ-UHFFFAOYSA-N 2-(4-azaniumylcyclohexyl)acetate Chemical compound NC1CCC(CC(O)=O)CC1 XVDSFSRMHSDHGJ-UHFFFAOYSA-N 0.000 description 1
- FCQHYITXTSIWDB-UHFFFAOYSA-N 2-(4-azaniumylpiperidin-1-yl)acetate Chemical compound NC1CCN(CC(O)=O)CC1 FCQHYITXTSIWDB-UHFFFAOYSA-N 0.000 description 1
- TXHAHOVNFDVCCC-UHFFFAOYSA-N 2-(tert-butylazaniumyl)acetate Chemical compound CC(C)(C)NCC(O)=O TXHAHOVNFDVCCC-UHFFFAOYSA-N 0.000 description 1
- HAAUVXXFRQXTTQ-UHFFFAOYSA-N 2-[4-(azaniumylmethyl)phenyl]acetate Chemical compound NCC1=CC=C(CC(O)=O)C=C1 HAAUVXXFRQXTTQ-UHFFFAOYSA-N 0.000 description 1
- KJVDDBLOGFNRTJ-UHFFFAOYSA-N 2-[amino(butyl)amino]acetic acid Chemical compound CCCCN(N)CC(O)=O KJVDDBLOGFNRTJ-UHFFFAOYSA-N 0.000 description 1
- DNWOZEQWCCXGRU-UHFFFAOYSA-N 2-azaniumyl-2-(2,3-difluorophenyl)acetate Chemical compound OC(=O)C(N)C1=CC=CC(F)=C1F DNWOZEQWCCXGRU-UHFFFAOYSA-N 0.000 description 1
- FSTDRNWTSCJIRN-UHFFFAOYSA-N 2-azaniumyl-2-(2,5-difluorophenyl)acetate Chemical compound OC(=O)C(N)C1=CC(F)=CC=C1F FSTDRNWTSCJIRN-UHFFFAOYSA-N 0.000 description 1
- MPMRMNOQJFWMMA-UHFFFAOYSA-N 2-azaniumyl-2-(3,4-difluorophenyl)acetate Chemical compound OC(=O)C(N)C1=CC=C(F)C(F)=C1 MPMRMNOQJFWMMA-UHFFFAOYSA-N 0.000 description 1
- UEFLPVKMPDEMFW-UHFFFAOYSA-N 2-azaniumyl-3-(2,4-difluorophenyl)propanoate Chemical compound OC(=O)C(N)CC1=CC=C(F)C=C1F UEFLPVKMPDEMFW-UHFFFAOYSA-N 0.000 description 1
- YHYQITHAFYELNW-UHFFFAOYSA-N 2-azaniumyl-3-(2,5-difluorophenyl)propanoate Chemical compound OC(=O)C(N)CC1=CC(F)=CC=C1F YHYQITHAFYELNW-UHFFFAOYSA-N 0.000 description 1
- QFGMPXZFCIHYIR-UHFFFAOYSA-N 2-azaniumyl-3-(3,5-difluorophenyl)propanoate Chemical compound OC(=O)C(N)CC1=CC(F)=CC(F)=C1 QFGMPXZFCIHYIR-UHFFFAOYSA-N 0.000 description 1
- DEBQMEYEKKWIKC-UHFFFAOYSA-N 2-azaniumyl-3-(4-fluoro-1h-indol-3-yl)propanoate Chemical compound C1=CC(F)=C2C(CC(N)C(O)=O)=CNC2=C1 DEBQMEYEKKWIKC-UHFFFAOYSA-N 0.000 description 1
- WTOFYLAWDLQMBZ-UHFFFAOYSA-N 2-azaniumyl-3-thiophen-2-ylpropanoate Chemical compound OC(=O)C(N)CC1=CC=CS1 WTOFYLAWDLQMBZ-UHFFFAOYSA-N 0.000 description 1
- KRNSHCKTGFAMPQ-UHFFFAOYSA-N 2-azaniumyl-4,4,4-trifluoro-3-(trifluoromethyl)butanoate Chemical compound OC(=O)C(N)C(C(F)(F)F)C(F)(F)F KRNSHCKTGFAMPQ-UHFFFAOYSA-N 0.000 description 1
- BAOLXXJPOPIBKA-UHFFFAOYSA-N 2-azaniumyl-4,4,4-trifluoro-3-methylbutanoate Chemical compound FC(F)(F)C(C)C(N)C(O)=O BAOLXXJPOPIBKA-UHFFFAOYSA-N 0.000 description 1
- RUEWGWBXZIDRJY-UHFFFAOYSA-N 2-azaniumyl-6,6,6-trifluorohexanoate Chemical compound OC(=O)C(N)CCCC(F)(F)F RUEWGWBXZIDRJY-UHFFFAOYSA-N 0.000 description 1
- NYCRCTMDYITATC-UHFFFAOYSA-N 2-fluorophenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1F NYCRCTMDYITATC-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- AJHPGXZOIAYYDW-UHFFFAOYSA-N 3-(2-cyanophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)CC1=CC=CC=C1C#N AJHPGXZOIAYYDW-UHFFFAOYSA-N 0.000 description 1
- GSWYUZQBLVUEPH-UHFFFAOYSA-N 3-(azaniumylmethyl)benzoate Chemical compound NCC1=CC=CC(C(O)=O)=C1 GSWYUZQBLVUEPH-UHFFFAOYSA-N 0.000 description 1
- XFXOLBNQYFRSLQ-UHFFFAOYSA-N 3-amino-2-naphthoic acid Chemical compound C1=CC=C2C=C(C(O)=O)C(N)=CC2=C1 XFXOLBNQYFRSLQ-UHFFFAOYSA-N 0.000 description 1
- XABCFXXGZPWJQP-UHFFFAOYSA-N 3-aminoadipic acid Chemical compound OC(=O)CC(N)CCC(O)=O XABCFXXGZPWJQP-UHFFFAOYSA-N 0.000 description 1
- CKTUXQBZPWBFDX-UHFFFAOYSA-N 3-azaniumylcyclohexane-1-carboxylate Chemical compound NC1CCCC(C(O)=O)C1 CKTUXQBZPWBFDX-UHFFFAOYSA-N 0.000 description 1
- ASBJGPTTYPEMLP-UHFFFAOYSA-N 3-chloroalanine Chemical compound ClCC(N)C(O)=O ASBJGPTTYPEMLP-UHFFFAOYSA-N 0.000 description 1
- BXRLWGXPSRYJDZ-UHFFFAOYSA-N 3-cyanoalanine Chemical compound OC(=O)C(N)CC#N BXRLWGXPSRYJDZ-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-PZFLKRBQSA-N 4-amino-3,5-ditritiobenzoic acid Chemical compound [3H]c1cc(cc([3H])c1N)C(O)=O ALYNCZNDIQEVRV-PZFLKRBQSA-N 0.000 description 1
- LRDIEHDJWYRVPT-UHFFFAOYSA-N 4-amino-5-hydroxynaphthalene-1-sulfonic acid Chemical compound C1=CC(O)=C2C(N)=CC=C(S(O)(=O)=O)C2=C1 LRDIEHDJWYRVPT-UHFFFAOYSA-N 0.000 description 1
- DPDPQQHHTHKSRN-UHFFFAOYSA-N 4-aminooxane-4-carboxylic acid Chemical compound OC(=O)C1(N)CCOCC1 DPDPQQHHTHKSRN-UHFFFAOYSA-N 0.000 description 1
- QJKGTQZAVYBRGG-UHFFFAOYSA-N 4-azaniumyl-5-(1h-indol-3-yl)pentanoate Chemical compound C1=CC=C2C(CC(CCC(O)=O)N)=CNC2=C1 QJKGTQZAVYBRGG-UHFFFAOYSA-N 0.000 description 1
- DRNGLYHKYPNTEA-UHFFFAOYSA-N 4-azaniumylcyclohexane-1-carboxylate Chemical compound NC1CCC(C(O)=O)CC1 DRNGLYHKYPNTEA-UHFFFAOYSA-N 0.000 description 1
- XWHHYOYVRVGJJY-QMMMGPOBSA-N 4-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-QMMMGPOBSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- XWHHYOYVRVGJJY-UHFFFAOYSA-N 4-fluorophenylalanine Chemical compound OC(=O)C(N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-UHFFFAOYSA-N 0.000 description 1
- BXRFQSNOROATLV-UHFFFAOYSA-N 4-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(C=O)C=C1 BXRFQSNOROATLV-UHFFFAOYSA-N 0.000 description 1
- GTVVZTAFGPQSPC-UHFFFAOYSA-N 4-nitrophenylalanine Chemical compound OC(=O)C(N)CC1=CC=C([N+]([O-])=O)C=C1 GTVVZTAFGPQSPC-UHFFFAOYSA-N 0.000 description 1
- JHHOFXBPLJDHOR-UHFFFAOYSA-N 4-phenylpyrrolidin-1-ium-2-carboxylate Chemical compound C1NC(C(=O)O)CC1C1=CC=CC=C1 JHHOFXBPLJDHOR-UHFFFAOYSA-N 0.000 description 1
- ABSTXSZPGHDTAF-BYPYZUCNSA-N 4S-aminopentanoic acid Chemical compound C[C@H](N)CCC(O)=O ABSTXSZPGHDTAF-BYPYZUCNSA-N 0.000 description 1
- XFGVJLGVINCWDP-UHFFFAOYSA-N 5,5,5-trifluoroleucine Chemical compound FC(F)(F)C(C)CC(N)C(O)=O XFGVJLGVINCWDP-UHFFFAOYSA-N 0.000 description 1
- INPQIVHQSQUEAJ-UHFFFAOYSA-N 5-fluorotryptophan Chemical compound C1=C(F)C=C2C(CC(N)C(O)=O)=CNC2=C1 INPQIVHQSQUEAJ-UHFFFAOYSA-N 0.000 description 1
- HUNCSWANZMJLPM-UHFFFAOYSA-N 5-methyltryptophan Chemical compound CC1=CC=C2NC=C(CC(N)C(O)=O)C2=C1 HUNCSWANZMJLPM-UHFFFAOYSA-N 0.000 description 1
- YMEXGEAJNZRQEH-UHFFFAOYSA-N 6-Fluoro-DL-tryptophan Chemical compound FC1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 YMEXGEAJNZRQEH-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- UQXNEWQGGVUVQA-UHFFFAOYSA-N 8-aminooctanoic acid Chemical compound NCCCCCCCC(O)=O UQXNEWQGGVUVQA-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- SILQDLDAWPQMEL-UHFFFAOYSA-N DL-indospicine Natural products OC(=O)C(N)CCCCC(N)=N SILQDLDAWPQMEL-UHFFFAOYSA-N 0.000 description 1
- 108010002156 Depsipeptides Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- NIGWMJHCCYYCSF-UHFFFAOYSA-N Fenclonine Chemical compound OC(=O)C(N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- FXLVSYVJDPCIHH-STQMWFEESA-N Gly-Phe-Arg Chemical group [H]NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FXLVSYVJDPCIHH-STQMWFEESA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 102000008015 Hemeproteins Human genes 0.000 description 1
- 108010089792 Hemeproteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- ZQISRDCJNBUVMM-UHFFFAOYSA-N L-Histidinol Natural products OCC(N)CC1=CN=CN1 ZQISRDCJNBUVMM-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- FSBIGDSBMBYOPN-VKHMYHEASA-N L-canavanine Chemical compound OC(=O)[C@@H](N)CCONC(N)=N FSBIGDSBMBYOPN-VKHMYHEASA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- GGLZPLKKBSSKCX-YFKPBYRVSA-N L-ethionine Chemical compound CCSCC[C@H](N)C(O)=O GGLZPLKKBSSKCX-YFKPBYRVSA-N 0.000 description 1
- ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical compound OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 description 1
- JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical compound OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
- DGYHPLMPMRKMPD-UHFFFAOYSA-N L-propargyl glycine Natural products OC(=O)C(N)CC#C DGYHPLMPMRKMPD-UHFFFAOYSA-N 0.000 description 1
- ZKZBPNGNEQAJSX-REOHCLBHSA-N L-selenocysteine Chemical compound [SeH]C[C@H](N)C(O)=O ZKZBPNGNEQAJSX-REOHCLBHSA-N 0.000 description 1
- DZLNHFMRPBPULJ-VKHMYHEASA-N L-thioproline Chemical compound OC(=O)[C@@H]1CSCN1 DZLNHFMRPBPULJ-VKHMYHEASA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- WMFYOYKPJLRMJI-UHFFFAOYSA-N Lercanidipine hydrochloride Chemical compound Cl.COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 WMFYOYKPJLRMJI-UHFFFAOYSA-N 0.000 description 1
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- FSBIGDSBMBYOPN-UHFFFAOYSA-N O-guanidino-DL-homoserine Natural products OC(=O)C(N)CCON=C(N)N FSBIGDSBMBYOPN-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 description 1
- RJFAYQIBOAGBLC-UHFFFAOYSA-N Selenomethionine Natural products C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108010077465 Tropocollagen Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 238000005575 aldol reaction Methods 0.000 description 1
- 125000002009 alkene group Chemical group 0.000 description 1
- 125000002355 alkine group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- QCTBMLYLENLHLA-UHFFFAOYSA-N aminomethylbenzoic acid Chemical compound NCC1=CC=C(C(O)=O)C=C1 QCTBMLYLENLHLA-UHFFFAOYSA-N 0.000 description 1
- 229960003375 aminomethylbenzoic acid Drugs 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- UHBYWPGGCSDKFX-UHFFFAOYSA-N carboxyglutamic acid Chemical compound OC(=O)C(N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-UHFFFAOYSA-N 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- LQJWIXKJNVDYHH-UHFFFAOYSA-N chloro-(3-isocyanatopropyl)-dimethylsilane Chemical compound C[Si](C)(Cl)CCCN=C=O LQJWIXKJNVDYHH-UHFFFAOYSA-N 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001520 comb Anatomy 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Chemical group CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 108010054812 diprotin A Proteins 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- FPIQZBQZKBKLEI-UHFFFAOYSA-N ethyl 1-[[2-chloroethyl(nitroso)carbamoyl]amino]cyclohexane-1-carboxylate Chemical compound ClCCN(N=O)C(=O)NC1(C(=O)OCC)CCCCC1 FPIQZBQZKBKLEI-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- QNRXNRGSOJZINA-UHFFFAOYSA-N indoline-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)CC2=C1 QNRXNRGSOJZINA-UHFFFAOYSA-N 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229920000592 inorganic polymer Polymers 0.000 description 1
- 229910001867 inorganic solvent Inorganic materials 0.000 description 1
- 239000003049 inorganic solvent Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 150000002668 lysine derivatives Chemical class 0.000 description 1
- VWHRYODZTDMVSS-QMMMGPOBSA-N m-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC(F)=C1 VWHRYODZTDMVSS-QMMMGPOBSA-N 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000013335 mesoporous material Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- UIUXUFNYAYAMOE-UHFFFAOYSA-N methylsilane Chemical compound [SiH3]C UIUXUFNYAYAMOE-UHFFFAOYSA-N 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- SJYQYOVTHISIKX-UHFFFAOYSA-N n,n-dimethylformamide;n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CN(C)C=O.CCN(C(C)C)C(C)C SJYQYOVTHISIKX-UHFFFAOYSA-N 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 239000002114 nanocomposite Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- CQYBNXGHMBNGCG-RNJXMRFFSA-N octahydroindole-2-carboxylic acid Chemical compound C1CCC[C@H]2N[C@H](C(=O)O)C[C@@H]21 CQYBNXGHMBNGCG-RNJXMRFFSA-N 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical compound CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- 229960002718 selenomethionine Drugs 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 125000005372 silanol group Chemical group 0.000 description 1
- 238000003980 solgel method Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000002336 sorption--desorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
- NPDBDJFLKKQMCM-UHFFFAOYSA-N tert-butylglycine Chemical compound CC(C)(C)C(N)C(O)=O NPDBDJFLKKQMCM-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 239000005341 toughened glass Substances 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- ORQXBVXKBGUSBA-QMMMGPOBSA-N β-cyclohexyl-alanine Chemical compound OC(=O)[C@@H](N)CC1CCCCC1 ORQXBVXKBGUSBA-QMMMGPOBSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
- C08G77/04—Polysiloxanes
- C08G77/22—Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen and oxygen
- C08G77/26—Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen and oxygen nitrogen-containing groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/042—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers characterised by the nature of the carrier
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N55/00—Biocides, pest repellants or attractants, or plant growth regulators, containing organic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen and sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
- B01J20/10—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
- B01J20/103—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate comprising silica
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/281—Sorbents specially adapted for preparative, analytical or investigative chromatography
- B01J20/286—Phases chemically bonded to a substrate, e.g. to silica or to polymers
- B01J20/289—Phases chemically bonded to a substrate, e.g. to silica or to polymers bonded via a spacer
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
- B01J20/3204—Inorganic carriers, supports or substrates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3214—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the method for obtaining this coating or impregnating
- B01J20/3217—Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond
- B01J20/3219—Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond involving a particular spacer or linking group, e.g. for attaching an active group
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3244—Non-macromolecular compounds
- B01J20/3246—Non-macromolecular compounds having a well defined chemical structure
- B01J20/3248—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such
- B01J20/3251—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such comprising at least two different types of heteroatoms selected from nitrogen, oxygen or sulphur
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3244—Non-macromolecular compounds
- B01J20/3246—Non-macromolecular compounds having a well defined chemical structure
- B01J20/3257—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one of the heteroatoms nitrogen, oxygen or sulfur together with at least one silicon atom, these atoms not being part of the carrier as such
- B01J20/3259—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one of the heteroatoms nitrogen, oxygen or sulfur together with at least one silicon atom, these atoms not being part of the carrier as such comprising at least two different types of heteroatoms selected from nitrogen, oxygen or sulfur with at least one silicon atom
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3268—Macromolecular compounds
- B01J20/3272—Polymers obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
- B01J20/3274—Proteins, nucleic acids, polysaccharides, antibodies or antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/72—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction of compounds containing >C = O groups with the same or other compounds containing >C = O groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Definitions
- the subject of the present patent application relates to new peptide-silane "hybrid block” molecules, their synthesis, their use for the preparation of new hybrid peptide-silica materials, themselves usable in various applications, for example at the level of medical equipment, separation of complex products or even in nanoparticles for imaging.
- silica-based organic-inorganic hybrid materials obtained by sol-gel processes have attracted considerable attention in recent decades. Indeed, these materials constitute a spectacular class of products combining properties of organic moieties on inorganic matrices (Loy, DA et al, Chem rev 95, 1431-1442 (1995) and Corriu, Angew Chem Int. 39, 1376-1398 (2000)). Materials comprising both mesoporous silica structural characteristics and peptide properties constitute a new class of bioorganic-inorganic hybrid materials that would find their place in catalysis, separation or molecular recognition techniques, for example.
- Hybrid materials can be obtained by a direct synthetic approach of functionalization of silica, that is to say by copolymerization of tetraethylorthosilicates (TEOS) and an organotrialkoxysilane having the desired function.
- TEOS tetraethylorthosilicates
- the organic fragment can be introduced by grafting the latter onto the already structured silicic material (post-synthesis).
- neuroactive "silane peptides” are disclosed for producing films (thin films), which are then used to modulate the phenotype of the carcinoma strain cell line. embryonic PI 9.
- the Colin Przybylowski et al. (J. Mater Chem., 2012, 22, 10672-10683) relates to the design of biological interfaces that stimulate cell differentiation.
- WO 00/461238 relates to solid support synthesis in which the solid support is vaporizable at the time of cleavage.
- the article by Carmen Coll et al. (Angew Chem et al., Ed., 2011, 50, 2138-2140) relates to mesoporous silica nanoparticles functionalized by peptide strands, which peptide strands, under the action of a protease, release host molecules.
- US 2011/0092672 discloses nanoparticles comprising a peptide-silicic molecular fragment on the surface of the nanoparticles.
- antimicrobial / antibiotic / antifungal materials whose effectiveness is proven, or tools to diversify the hybrid materials obtained by C-terminal grafting of the peptide chain or on the side chain. peptides.
- the present invention allows a controlled grafting of molecules of interest with an extended potential both in terms of the grafting rate and the nature of the chemical bonds between the peptide chains and the silicic support by the use of perfectly defined hybrid elementary blocks. .
- the present invention also makes it possible to synthesize ab initio materials by using perfectly defined hybrid elementary blocks as precursors, thus enabling the production of new materials with innovative characteristics.
- the subject of the present invention relates to a peptide conjugate of formula
- A is a peptide fragment
- Y 2 , Y 3 which may be identical or different, each independently represent a hydrogen atom, a halogen atom or an OR 2 radical in which R 2 represents a hydrogen atom an aryl group or a saturated or unsaturated aliphatic hydrocarbon chain containing 1 to 6 carbon atoms optionally substituted with an aryl, halogen or hydroxyl group,
- n is an integer between 1 to 50, preferably 1 to 10.
- the peptide conjugate (I) is not one of the following structures H-YGGFLR-NH-CH 2 -CH 2 -CH 2 -Si (OH) 3, H-YGGFLR-NH-CH 2 -CH 2 -CH 2 -Si (OH) 2 F or H-YGGFLR-NH-CH 2 -CH 2 -CH 2 -Si (OH) F 2 .
- A is a peptide fragment
- Y 2 , Y 3 which may be identical or different, each independently represent a hydrogen atom, a halogen atom or an OR 2 radical in which R 2 represents a hydrogen atom an aryl group or a saturated or unsaturated aliphatic hydrocarbon chain containing 1 to 6 carbon atoms optionally substituted with an aryl, halogen or hydroxyl group,
- n is an integer between 1 to 50, preferably 1 to 10, characterized in that:
- the peptide conjugate of formula (I), in which A is a linear peptide fragment comprises a single Si carried via an X group on the alpha amine at the N-terminus of the fragment A, then
- A is a peptide fragment selected from the group consisting of an antibiotic, an antimicrobial, an antifungal, an anti-inflammatory, a catalyst, a biological receptor ligand and an enzyme inhibitor, preferably an antibiotic, an antimicrobial, an antifungal an anti-inflammatory and a catalyst, more preferably an antibiotic, an antimicrobial, an antifungal and an anti-inflammatory, more preferably an antibiotic, an antimicrobial and an antifungal, more preferably an antibiotic and an antimicrobial;
- Yi is different from Y 2 and / or Y 3
- the peptide conjugate (I) is not one of the following structures H-YGGFLR-NH-CH 2 -CH 2 -CH 2 -Si (OH) 3 , H-YGGFLR-NH-CH 2 -CH 2 - CH 2 - Si (OH) 2 F or H-YGGFLR-NH-CH 2 -CH 2 -CH 2 -Si (OH) F 2 ..
- H-YGGFLR-NH-CH 2 -CH 2 -CH 2 - Si (OH) 3 H-YGGFLR-NH-CH 2 -CH 2 -CH 2 -Si (OH) 2 F and H-YGGFLR-NH-CH 2 -CH 2 -CH 2 -Si (OH) F 2 .
- the subject of the present invention relates to a peptide conjugate as described above characterized in that:
- Y 1 , Y 2 , Y 3 and X are as previously defined,
- Zi represents a side chain of a naturally occurring amino acid optionally substituted with a protecting group
- * represents the bond by which the fragment ( ⁇ ) is connected to the remainder of the peptide conjugate
- A is a peptide fragment selected from the group consisting of an antibiotic, an antimicrobial, an antifungal, an anti-inflammatory, a catalyst, a biological receptor ligand and an enzyme inhibitor, preferably an antibiotic, an antimicrobial, an antifungal an anti-inflammatory agent and a catalyst, more preferably an antibiotic, an antimicrobial agent, an antifungal agent and an anti-inflammatory agent, even more preferably an antibiotic, an antimicrobial agent and an antifungal agent, more preferably an antibiotic and an antimicrobial agent,
- Another object of the present invention relates to a method to synthesis of peptide conjugates defined above (including H-YGGFLR-NH-CH 2 structures - CH 2 -CH 2 -Si (OH) 3, H-YGGFLR- NH-CH 2 -CH 2 -CH 2 -Si (OH) 2 F and / or H-YGGFLR-NH-CH 2 -CH 2 -CH 2 -Si (OH) F 2 ), characterized in that it comprises the steps :
- X ' is a group X as defined above activated for example by means of an isocyanate, an azide, an aldehyde, an activated carboxylic acid such as an acyl chloride, or still a group -CO-NH-NH 2 , Y 1 , Y 2 , Y 3 are as defined as above.
- one aspect of the present invention relates to the use of a peptide conjugate defined above for incorporating a peptide strand of formula A into a silicic material or a metal oxide.
- the object of the present invention thus also relates to a synthetic mixture intended for the manufacture of hybrid peptide-silicic materials, characterized in that:
- said synthetic mixture contains at least one peptide conjugate as defined herein;
- said synthetic mixture optionally contains a preferentially organic or inorganic solvent ,.
- said synthetic mixture optionally contains another organic or inorganic monomer or polymer.
- said synthetic mixture optionally contains a catalyst for the polymerization.
- the object of the present invention further relates to a method ⁇ characterized by the following steps:
- step ii) condensation, optionally in situ, of the peptide conjugate obtained according to step i) on a support material, preferably selected from silica, mesoporous silica, silica nanoparticles, glass, a metal oxide, iii) step optional rinsing, preferably with a water-miscible organic solvent such as DMF, acetone, DMSO,
- the subject of the present invention relates to a ⁇ -silicic material grafted with peptide strands A as defined above that can be obtained by the ⁇ process defined above, with the exception of the cases where:
- the peptide strand A is a peptide sequence consisting of a poly-Ala, poly-Lys, poly-Met, poly-Glu (OBzl) or poly-Glu fragment,
- the support material consists of glass beads, or even consists of glass, and / or
- the ⁇ -silicic copolymeric material of peptide strands A does not comprise a protected YGGFLR fragment (Boc strategy in particular) or deprotected.
- the ⁇ -silicic copolymeric material of peptide strands A does not comprise a poly-Pro fragment, in particular a proline dimer, a proline trimer and / or a proline tetramer.
- the ⁇ -silicic copolymeric material of peptide strands A does not comprise a poly-Val fragment.
- the ⁇ -silicic copolymeric material of peptide strands A does not comprise any monomer, dimer or trimer of the protected GDEVDG fragment (Fmoc strategy in particular) or deprotected.
- the ⁇ -silicic copolymeric material of peptide strands A does not include the protected AAEAYAKELAEANMAKG fragment (Fmoc strategy in particular) or deprotected.
- the ⁇ -silicic copolymeric material of peptide strands A does not include the protected Cys-Lys-Gly-Arg-Gly-Asp fragment (Fmoc strategy in particular) or deprotected.
- the object of the present invention also relates to the use of the material ⁇ defined above for the catalysis of chemical reactions, the separation of products by chromatography, the functionalization of nanoparticles, the production of biocompatible matrix for the treatment of injuries and / or burns, obtaining material for electronic or ionic facilitated transport, fabrication of nanosensors, fabrication of printed circuits, preparation of antimicrobial surfaces, surface preparation promoting cellular regrowth to cover medical devices , or the silica particles used in the cosmetic formulation.
- An object of the present invention further relates to a method ⁇ characterized by the following steps:
- step i) activation of any of the groups Y 1 , Y 2 , and / or Y 3 of the peptide conjugate defined as above, preferably by hydrolysis, ii) condensation, optionally in situ, of the peptide conjugate obtained according to step i) with a silica precursor, such as silicic acid, a C 1 -C 10 silicate or tetraalkoxysilane, more particularly tetraethoxysilane, iii) optional rinsing step, preferably with a water-miscible organic solvent such as DMF, acetone, DMSO,
- a silica precursor such as silicic acid, a C 1 -C 10 silicate or tetraalkoxysilane, more particularly tetraethoxysilane
- step iii) optional rinsing step, preferably with a water-miscible organic solvent such as DMF, acetone, DMSO,
- the subject of the present invention relates to a silicic copolymer material ⁇ of peptide strands A as defined above which can be obtained by the ⁇ process, advantageously the ⁇ -peptide silicic copolymeric material of peptide strands A is a mesoporous silica, a film, a gel, a suspension or a solution.
- the silicic copolymer material ⁇ of peptide strands A does not comprise a poly-Ala, poly-Lys, poly-Met, poly-Glu (OBzl) or poly-Glu fragment.
- the silicic copolymer material ⁇ of peptide strands A does not comprise a poly-Pro fragment, in particular a proline dimer, a proline trimer and / or a proline tetramer.
- the silicic copolymer material ⁇ of peptide strands A does not comprise a poly-Val fragment, in particular a valine dimer.
- the silicic copolymer material ⁇ of peptide strands A does not comprise a protected YGGFLR fragment (Boc strategy in particular) or deprotected.
- the silicic copolymer material ⁇ of peptide strands A does not comprise any monomer, dimer or trimer of the GDEVDG fragment.
- the silicic copolymer material ⁇ of peptide strands A does not comprise the protected AAEAYAKELAEANMAKG fragment (Fmoc strategy in particular) or deprotected.
- the silicic copolymer material ⁇ of peptide strands A does not include the protected Cys-Lys-Gly-Arg-Gly-Asp fragment (Fmoc strategy in particular) or deprotected.
- the object of the present invention also relates to the use of the material ⁇ as defined above for the catalysis of chemical reactions, the separation of products by chromatography, the functionalization of nanoparticles, the production of biocompatible matrix for the treatment of wounds and / or burns, the manufacture of nanosensors, the manufacture of printed circuits, the preparation of antimicrobial surfaces, or the surface preparation promoting cellular regrowth to cover medical devices.
- Another subject of the present invention relates to a method ⁇ characterized by the following steps:
- TFA trifluoroacetic acid
- the subject of the present invention relates to a silicic copolymeric material ⁇ of peptide strands A as defined above which can be obtained by the ⁇ process.
- the silicic copolymeric material ⁇ of peptide strands A does not comprise a poly-Ala, poly-Lys, poly-Met, poly-Glu (OBzl) or poly-Glu fragment.
- the silicic copolymeric material ⁇ of peptide strands A does not comprise a poly-Pro fragment, in particular a proline dimer, a proline trimer and / or a proline tetramer.
- the silicic copolymeric material ⁇ of peptide strands A does not comprise a poly-Val fragment, in particular a valine dimer.
- the silicic copolymeric material ⁇ of peptide strands A does not comprise a protected YGGFLR fragment (Boc strategy in particular) or deprotected.
- the silicic copolymeric material ⁇ of peptide strands A does not comprise any monomer, dimer or trimer of the GDEVDG fragment.
- the silicic copolymeric material ⁇ of peptide strands A does not comprise the protected AAEAYAKELAEANMAKG fragment (Fmoc strategy in particular) or deprotected.
- the silicic copolymeric material ⁇ of peptide strands A does not include the protected Cys-Lys-Gly-Arg-Gly-Asp fragment (Fmoc strategy in particular) or deprotected.
- the object of the present invention also relates to the use of the material ⁇ as defined above for the catalysis of chemical reactions, the separation of products by chromatography, the functionalization of nanoparticles, the production of biocompatible matrix for the treatment of wounds and / or burns, obtaining material for electronic or ionic facilitated transport, preparation of antimicrobial surfaces, surface preparation promoting cellular regrowth to cover medical devices, or silica particles entering the cosmetic formulation.
- conjugate refers to fragment "A" linked to the remainder of the molecule according to formula I.
- peptide should be understood as a polymer of amino acids, said amino acids being linked together by a peptide bond and / or pseudopeptide.
- a peptide generally contains between 2 and 80 to 100 amino acids, the upper limit not being clearly defined.
- Fragment A contains between 2 and 80 amino acids, more preferably between 3 and 40, and even more preferably between 4 and 20.
- spacer there is included a fragment comprising at least one atom.
- the spacer group contains at least one carbon atom.
- the spacer group makes it possible to reduce the steric hindrance between the peptide and the Si. More advantageously, the spacer group allows the silicate group to react with a limited annoyance of the fragment A. In addition, the spacer group allows a stable bond between the fragment A. and Si, while allowing the silicate moiety to react. It is therefore clear that the spacer group can not be an amino acid residue (i.e., a fused amino acid), or a peptide chain (i.e., a condensed peptide) .
- the spacer group comprises, or consists of, a saturated or unsaturated aliphatic hydrocarbon chain.
- the spacer group may furthermore include heteroatoms, in particular chosen from N, O, S or P, and may in addition be substituted, in particular by halogen atoms, or by hydroxyl groups, aryl groups, and alkyl groups. C 1 -C 4 , sulphates, amines, or phosphates.
- heteroatoms are present in the spacer moiety, preferably these heteroatoms are not directly connected to Si.
- the spacer group is a linear or branched C 1 -C 4 alkyl moiety. More preferably, the spacer group is a moiety - (CH 2 ) 2 -, - (CH 2 ) 3 -, - (CH 2 ) 4 -. Even more preferably, the spacer group is a - (CH 2 ) 3 - fragment.
- aliphatic saturated or unsaturated hydrocarbon chain is inclusive of alkyl type moieties C 1 -C 10 alkene, C 2 -Cio or alkyne, C 2 -C 10.
- C 1 -C 10 alkyl or "alkyl of 1 to 10 carbon atoms”, a saturated, cyclic, linear or branched aliphatic group containing from 1 to 10 carbon atoms. carbon, such as methyl, ethyl, isopropyl, tert-butyl, n-pentyl, etc.
- C2-C10 alkene or “alkene of 2 to 10 carbon atoms” group is meant for the purposes of the present invention, a linear or branched, mono- or polyunsaturated aliphatic group comprising from 2 to 10 carbon atoms.
- An alkene group according to the invention preferably comprises one or more ethylenic unsaturations.
- C2-C10 alkyne or “alkyne of 2 to 10 carbon atoms” is meant for the purpose of the present invention, an aliphatic group, linear or branched, comprising from 2 to 10 carbon atoms and at less a double unsaturation, that is to say a triple bond between two carbon atoms.
- An alkyne group according to the invention preferably comprises one or more double unsaturations.
- C 1 -C 10 alcohol a linear or branched, saturated aliphatic C 1 -C 12 alkyl group, as defined above, comprising at least one OH group.
- alcohols may be ethanol, isopropanol, propanol, butanol, isobutanol, t-butanol, etc.
- C3-C10 ketone a linear, cyclic or branched, saturated aliphatic C 1 -C 10 alkyl group, as defined above, comprising at least one carbonyl group inserted between two carbons.
- a ketone group may be acetone, butan-2-one or pentan-2-one.
- C1-C10 diketone two carbonyl groups, juxtaposed to each other or not, included in a C 2 -C 6 alkyl chain.
- a diacetone group may be acetyl acetone.
- C 3 -C 10 ester is understood to mean a C 1 -C 8 alkyl group covalently linked to another C 1 -C 6 alkyl group via a COO group, the total of the number of carbons being between 3 and 10.
- an ester group may be ethyl acetate.
- C 1 -C 10 ether a C 1 -C 9 alkyl group covalently linked to another C 1 -C 9 alkyl group via an oxygen the total number of carbons being between 2 and 10.
- an ether group may be diethyl ether.
- C 1 -C 10 haloalkyl a C 1 -C 10 alkyl group covalently linked to one or more halogen atoms, such as a chlorine or fluorine atom. , iodine or bromine.
- a haloalkyl group may be dichloromethane, chloroform or methyl iodide.
- C 1 -C 10 alkyl substituted with one or more nitriles a C 1 -C 10 alkyl group as defined above, covalently linked to one or more CN groups. , such as acetonitrile.
- cyclic lactam a C 3 -C 10 alkyl ring in which is inserted a CO-NH group, optionally substituted by a C 1 -C 10 alkyl group, such as a grouping methyl, ethyl, isopropyl, tert-butyl, n-pentyl, etc.
- An example of a cyclic lactam may be N-methyl-2-pyrrolidone (NMP).
- arylene represents a substituent of an organic compound derived from an aryl moiety in which at least one hydrogen atom has been removed from two carbons included in aryl.
- it is a phenethyl group.
- aryl group is meant an aromatic group, preferably comprising from 5 to 10 carbon atoms, comprising one or more rings and optionally comprising one or more heteroatoms (s), in particular oxygen, nitrogen or sulfur, such as for example a phenyl, furan, indole, pyridine, naphthalene, etc. group.
- silic material is understood to mean silica in these different forms, such as common commercial silica, for example as Corning®7980 silica, mesoporous silica, whether ordered or otherwise, and SiO 2 nanoparticles.
- the support is mesoporous silica, such as silica SBA, MCM, or HMS.
- metal oxide is meant metal oxides in the general sense such as Ti0 2 , Sn0 2 , ZnO, Fe 2 0 3 or mixtures thereof.
- an "antimicrobial activity" is the generic definition as understood by those skilled in the art, i.e., an effect relative to an antimicrobial agent.
- An antimicrobial agent is a substance that kills, slows growth or blocks the growth of one or more microbes.
- growth is understood within the scope of the present invention any cellular operation allowing a volumetric increase of the cell, cell division or cell reproduction.
- a microbe in the context of the present invention relates to any unicellular or multicellular pathogenic or parasitic organisms of other living organisms such as humans. Antibiotic activity
- Antibiotic activity is the generic definition as understood by those skilled in the art, that is to say an effect relative to an antibiotic agent.
- An antibiotic is a substance that kills, slows down growth, or blocks the growth of one or more bacteria.
- growth is understood within the scope of the present invention any cellular operation allowing a volumetric increase of the cell (bacterium), cell division (of the bacterium) or cell reproduction (of the bacterium).
- Antifungal activity is the generic definition as understood by those skilled in the art, i.e., an effect relative to an antifungal agent.
- Antifungal agent is a substance that kills, slows growth or blocks the growth of one or more fungi.
- growth it is understood within the scope of the present invention any cellular operation allowing a volumetric increase of the cell (fungus), cell division (of the fungus) or cell reproduction (of the fungus).
- anti-adhesive surfaces it is understood in the present invention that the surfaces described in the present manuscript, have an anti-adhesive effect, an anti-biofilm accumulated or not to a cell lysis effect, slowing of cell growth and / or or blocking the cell growth of microbes.
- antibiotic surfaces it is understood in the present invention that the surfaces described in the present manuscript, have an anti-adhesive effect, anti-biofilm accumulated or not to a bactericidal, bacteriostatic effect (the bacteria are lysed, can no longer divide or grow, and / or reproduce).
- Antifungal surfaces By “antifungal surfaces”, it is understood in the present invention that the surfaces described in the present manuscript, have an anti-adhesive effect, anti-biofilm accumulated or not to a cell lysis effect, slowing of cell growth and / or or blocking cell growth of fungi.
- a natural peptide is a peptide found in the environment without direct human intervention (except its extraction / isolation)
- a synthetic peptide is a peptide that is not found in the environment without direct human intervention (apart from its extraction / isolation).
- a synthetic peptide may be a sequence of a natural peptide in which at least one natural amino acid has been replaced by another, natural or synthetic.
- linear peptide it is understood that all the amino acids of the peptide are linked in their sequential order and that the peptide has an N-terminus and a C-terminus.
- cyclic peptide there is included an amino acid sequence having no N-terminus or C-terminus.
- a cyclic peptide can be linked by a side chain to the solid support, and then the general definition applies, or it can be connected to the support by one of its N-termini or C-terminal and then the cycle is closed through at least one side chain of an amino acid.
- S-S (or Se-Se) linked peptides which some term cyclic, are not included in the present cyclic peptide definition.
- Peptides possessing an N-terminal and a C-terminal, an S-S bridge or Se-Se are not considered in the present invention as cyclic peptides. They are included either in the synthetic peptides category or in the natural peptides category.
- a pseudopeptide is a peptide comprising at least one pseudopeptide bond.
- One of the two amino acids can therefore be unnatural or replaced by a non-amino acid analogue having functions required for the pseudopeptide bond, for example a diamine or a diacid of the malonate type.
- pseudopeptide bonds the various reactive groups of amino acids can also be protected.
- the term "pseudopeptides” thus also includes compounds having pseudopeptide whose reactive groups such as those of the side chains are protected.
- An example of a preferred pseudopeptide are the depsipeptides, that is to say the peptides of which at least one peptide bond has been replaced by an ester-COO- bond.
- amino acid should be understood as any molecule having at least one carboxylic acid, at least one amine and at least one carbon connecting this amine and this carboxylic acid.
- amino acids that can be used in the context of the present invention are the so-called “natural” amino acids and / or synthetic amino acids as defined below.
- amino acids of the present invention are of L-form.
- natural amino acid represents, inter alia, the following amino acids: glycine (Gly), alanine (Ala), valine (Val), leucine (Leu), isoleucine (Ile), serine (Ser), threonine (Thr), phenylalanine (Phe), tyrosine (Tyr), tryptophan (Trp), cysteine (Cys), methionine (Met), proline (Pro), aspartic acid (Asp), asparagine (Asn), glutamine (Gin), glutamic acid (Glu), histidine (His), arginine (Arg) and lysine (Lys).
- the natural amino acids that are preferred according to the present invention are the amino acids of the L series. Synthetic amino acid
- synthetic amino acid includes all non-natural amino acids as defined above. These synthetic amino acids can be chosen from: ⁇ -alanine, allylglycine, tert-leucine, norleucine (Nie), 3-aminoadipic acid, 2-aminobenzoic acid, 3- aminobenzoic acid, 4-aminobenzoic acid, 2-aminobutanoic acid, 4-amino-1-carboxymethyl piperidine, 1-amino-1-cyclobutanecarboxylic acid, 4-aminocyclohexaneacetic acid, 1-amino acid cyclohexanecarboxylic acid, (1R, 2R) -2-aminocyclohexanecarboxylic acid, (1R, 2S) -2-aminocyclohexanecarboxylic acid, (1S, 2R) -2-aminocyclohexanecarboxylic acid, (1S, 2R) -2-aminocyclohexanecarboxy
- side chain of an amino acid represents the moiety carried by the ⁇ -carbon of an amino acid.
- side chains of naturally occurring amino acids such as glycine, valine, alanine and aspartic acid correspond to hydrogen, isopropyl, methyl and CH 2 COOH respectively.
- Side chains of other amino acids may be included in the definition of an amino acid side chain, such as those of the following amino acids: 4-amino-tetrahydropyran-4-carboxylic acid, allylglycine, diamino-butyric acid, diamino propionic acid , aminoserine, aminobutyric acid, amino butylglycine, phenylglycine, 4-chloro-phenylalanine, 4-fluoro-phenylalanine, 4-nitrophenylalanine, citrulline, cyclohexylalanine, thienylalanine, and the like.
- amino acids such as those of the following amino acids: 4-amino-tetrahydropyran-4-carboxylic acid, allylglycine, diamino-butyric acid, diamino propionic acid , aminoserine, aminobutyric acid, amino butylglycine, phenylglycine, 4-chloro-phenylalan
- the side chains of the amino acids may be protected by protecting groups (P) and more particularly N-protecting, O-protecting or S-protecting groups when these chains contain the corresponding heteroatoms.
- P protecting groups
- the protection of some of the reactive functions of the peptides is mandatory during the synthesis of said peptides.
- peptide synthesis is conventionally done by activating the carboxylic acid function of an amino acid, or an amino acid chain, by the use of a coupling agent. This activated acid is placed in the presence of an amino acid, or a chain of amino acids, whose terminal amine is not protected, thus resulting in the formation of an amide bond, also called peptide bond.
- the coupling conditions as well as the coupling agents used are very well known to those skilled in the art.
- Protecting groups (P) are also groups known to those skilled in the art. These protective groups and their use are described in books such as, for example, Greene, “Protective Groups in Organic Synthesis”, Wiley, New York, 2007 4th edition; Harrison et al. "Compendium of Synthetic Organic Methods", Vol. 1 to 8 (J. Wiley & sons, 1971 to 1996).
- a hydroxyl may be protected with a trityl group, or a carboxylic acid may be protected as a tert-butyl ester.
- a solid support synthesis it is the resin which serves as a protective group for the C-terminal carboxylic function.
- amino group (i.e. "alpha-amine") of the amino acid can be effected for example by a tert-butyloxycarbonyl group (hereinafter referred to as Boc-) or a group -9 -fluorenylmethyloxycarbonyl (hereinafter referred to as Fmoc-) represented by the formula:
- protection by the Boc-group can be obtained by reacting the amino acid with di-tert-butylpyrocarbonate (Boc 2 0).
- the amino acids obtained are synthetic until the removal of the protective group (s), thus releasing the so-called natural amino acid.
- Peptide synthesis is conventionally done by activating the carboxylic acid function of an amino acid, or an amino acid chain, by the use of a coupling agent.
- This activated acid is placed in the presence of an amino acid, or a chain of amino acids, whose terminal amine is not protected, thus resulting in the formation of an amide bond, also called peptide bond.
- the coupling conditions and the coupling agents used are very well known to those skilled in the art and described for example in books such as Greene, "Protective Groups in Organic Synthesis", Wiley, New York, 2007 4th edition; Harrison et al. "Compendium of Synthetic Organic Methods", Vol. 1 to 8 (J. Wiley & sons, 1971 to 1996).
- the peptide conjugate of formula (I) is characterized in that the peptide fragment A is a linear natural peptide strand, a linear synthetic peptide strand, a linear protected natural peptide strand, a peptide strand.
- synthetic protected linear one strand linear natural pseudopeptide, a linear synthetic pseudopeptide strand, a linear protected natural pseudopeptide strand, or a linear protected synthetic pseudopeptide strand, or the peptide fragment A comprises or consists of a cyclic natural peptide fragment, a cyclic synthetic peptide fragment, a natural peptide fragment cyclic protected peptide fragment, cyclic cyclic pseudopeptide fragment, cyclic synthetic pseudopeptide fragment, cyclic protected pseudopeptide fragment or cyclic protected synthetic pseudopeptide fragment.
- the peptide conjugate of formula (I) is characterized in that Yi represents a fragment different from Y 2 , and / or Y 3 .
- Y 1 represents an OR 2 radical in which R 2 represents a hydrogen atom, an aryl group or a saturated or unsaturated aliphatic hydrocarbon chain containing from 1 to 6 carbon atoms optionally substituted with an aryl or halogen group, or hydroxyl and the groups Y 2 and / or Y 3 represent a hydrogen atom or a halogen atom.
- Y 1 represents a radical OR 2 in which R 2 represents a methyl or an ethyl, and the groups Y 2 and / or Y 3 represent a hydrogen atom or a halogen atom.
- Y 1 represents a radical OR 2 in which R 2 represents a methyl or an ethyl, and the groups Y 2 and / or Y 3 represent a hydrogen, chlorine or fluorine atom.
- Y 1 represents a radical OR 2 in which R 2 represents a methyl or an ethyl, and the groups Y 2 and / or Y 3 represent a chlorine or fluorine atom.
- the peptide conjugate of formula (I) is characterized in that Y 1 and Y 2 represent, independently of each other, a radical OR 2 in which R 2 represents a hydrogen atom an aryl group or a saturated or unsaturated aliphatic hydrocarbon chain containing from 1 to 6 carbon atoms optionally substituted by an aryl, halogen, or hydroxyl and the groups Y 3 represents a hydrogen atom or a halogen atom.
- Y 1 and Y 2 represent, independently of one another, a radical OR 2 in which R 2 represents a methyl or an ethyl, and the group Y 3 represents a hydrogen atom or a halogen atom. .
- Y 1 and Y 2 represent, independently of one another, a radical OR 2 in which R 2 represents a methyl or an ethyl, and the group Y 3 represents a hydrogen, chlorine or fluorine.
- Y 1 and Y 2 represent, independently of one another, a radical OR 2 in which R 2 represents a methyl or an ethyl, and the group Y 3 represents a chlorine or fluorine atom.
- the peptide conjugate of formula (I) is characterized in that the peptide fragment A comprises between 2 and 80 amino acids, preferably between 2 and 30 amino acids.
- the peptide conjugate of formula (I) is characterized in that the peptide fragment is an antibiotic, an antimicrobial agent, an antifungal agent, an antiviral agent, an anti-inflammatory agent, a catalyst or a peptide fragment. structured, a biological receptor ligand and / or an enzyme inhibitor.
- the peptide conjugate of formula (I) is characterized in that the peptide fragment is an antibiotic, an antimicrobial, an antifungal, an anti-inflammatory, a catalyst, a receptor ligand and / or an enzyme inhibitor.
- the peptide conjugate of formula (I) is characterized in that the peptide fragment is an antibiotic, an antimicrobial, an antifungal and / or an anti-inflammatory. Even more advantageously, in one embodiment according to the present invention, the peptide conjugate of formula (I) is characterized in that the peptide fragment is an antibiotic, an antimicrobial and / or an antifungal.
- the peptide conjugate of formula (I) is characterized in that the peptide fragment is an antibiotic and / or an antimicrobial.
- the peptide conjugate of formula (I) is characterized in that the ratio of Si: N in mole included in the conjugate is between 1: 0.3 to 1: 100, preferentially between 1: 1 to 1:30, and even more preferably between 1: 2 and 1:15.
- the peptide conjugate of formula (I) is characterized in that it comprises at least one of the following fragments of formulas (II), (III) and / or (IV):
- Y 1 , Y 2 , and Y 3 are as defined above, X 1 , X 2 , X 3 , which are identical or different, each represent, independently of one another, a spacer group as defined above,
- Zi, Z 3 which may be identical or different, each represent, independently of one another, a side chain of a natural amino acid optionally substituted by a protective group,
- Z 2 represent a side chain of a natural amino acid substituted by X 2 or a bond
- R3 represents the N-terminal fragment of the peptide strand, a hydrogen atom or an N-protecting group
- R4 represents the C-terminal fragment of the peptide strand, a hydrogen atom, a group -NH 2 , a group -OR 5 , in which R 5 represents a hydrogen atom or an alkyl radical of 1 to 10 carbon atoms , or an atom or a carbonyl activating group such as a halogen atom or a succinimide group,
- * represents the bond (s) by which the fragments are connected to the rest of the peptide conjugate.
- the groups Y 1 , Y 2 , and Y 3 represent OR 2 in which R 2 represents a hydrogen atom, an aryl group or a saturated aliphatic hydrocarbon chain containing from 1 to 6 carbon atoms. More preferably, R 2 represents a saturated aliphatic hydrocarbon chain containing from 1 to 6 carbon atoms, more preferably still selected from methyl, ethyl and propyl.
- the ⁇ silicic material is grafted with peptide strands A as defined above and is capable of being obtained by the ⁇ method, except where the X group is one any of the following groupings:
- bonds * represent the bonds linked to the peptide fragment and the bonds ** represent the bonds connected to Si.
- a particular embodiment according to the present invention thus also relates to a synthetic mixture intended for the manufacture of hybrid peptide-silicic antibiotic, antimicrobial, antifungal and / or anti-inflammatory materials, characterized in that:
- said synthetic mixture contains at least one peptide conjugate as defined herein;
- said synthetic mixture optionally contains a solvent, preferably organic alcohol such as a C1-C10, a ketone C 3 - Cio, a diketone C4-C10, a C 3 -Cio ester, ether, C 2 -C 10 , C 1 -C 10 haloalkyl, C 1 -C 10 alkyl substituted by one or more nitriles, cyclic lactam optionally substituted with C 1 -C 10 alkyl, C 1 -C 10 alkyl substituted aryl, formamide substituted with 2-C 1 -C 10 alkyl, or inorganic such as water;
- a solvent preferably organic alcohol such as a C1-C10, a ketone C 3 - Cio, a diketone C4-C10, a C 3 -Cio ester, ether, C 2 -C 10 , C 1 -C 10 haloalkyl, C 1 -C 10 alkyl substitute
- said synthetic mixture optionally contains an additional organic or inorganic polymer selected from SiZ A4_ P P Q Z and A 3 _ q Si-Q RB and Z A 3 _ qIf-RB-SiZ Q A 3 _ q in which:
- Z and A are independently selected from hydrogen, chlorine, bromine or a hydroxy, methoxy, ethoxy, phenoxy, methyl, ethyl, propyl, isopropyl group;
- p 0, 1, 2 and 3;
- q 0, 1 and 2;
- RB represents a spacer arm preferably comprising a polyethylene glycol or poloxamer fragment (that is to say triblock copolymers of poly (ethylene glycol) -poly (propylene glycol) -poly (ethylene glycol)) having a mass of between 400 and 50,000. Daltons, preferably between 1000 and 20000 Daltons, more preferentially between 4000 and 15000 Daltons, (for example a triblock copolymer of the P123® or F127® type which are copolymers of poly (ethylene glycol) -poly (propylene glycol) -poly (ethylene glycol) of about 5800 Daltons and 12600 Daltons respectively).
- a polyethylene glycol or poloxamer fragment that is to say triblock copolymers of poly (ethylene glycol) -poly (propylene glycol) -poly (ethylene glycol) having a mass of between 400 and 50,000. Daltons, preferably between 1000 and 20000 Daltons, more preferentially between 4000 and 15000 Daltons
- said synthetic mixture optionally contains a polymerization-enabling catalyst, if appropriate, preferably chosen from an inorganic acid, an organic acid, an inorganic base or an organic base, a metal or organometallic complex.
- a polymerization-enabling catalyst if appropriate, preferably chosen from an inorganic acid, an organic acid, an inorganic base or an organic base, a metal or organometallic complex.
- the synthetic mixture intended for the manufacture of hybrid antibiotic, antimicrobial and / or antifungal peptide-silicic materials as above characterized in that:
- said synthetic mixture optionally contains a solvent, preferably chosen from acetone, acetylacetone, ethyl acetate, THF, Et 2 O, iPr 2 O, CHCl 3 , CH 2 Cl 2 , MeCN, NMP, DMSO, toluene and DMF, R A OH in which R A may represent a hydrogen atom, a methyl, ethyl, propyl, isopropyl or butyl group.
- a solvent preferably chosen from acetone, acetylacetone, ethyl acetate, THF, Et 2 O, iPr 2 O, CHCl 3 , CH 2 Cl 2 , MeCN, NMP, DMSO, toluene and DMF, R A OH in which R A may represent a hydrogen atom, a methyl, ethyl, propyl, isopropyl or butyl group.
- the synthetic mixture intended for the manufacture of hybrid antibiotic, antimicrobial and / or antifungal peptide-silicic materials as above is characterized in that the said synthetic mixture contains an acidic catalyst allowing the polymerization, chosen from HF, HC1. , HBr, HI, HNO 3 , H 2 SO 4 , CH 3 COOH,
- the synthetic mixture intended for the manufacture of hybrid antibiotic, antimicrobial and / or antifungal peptide-silicic materials as above is characterized in that the said synthetic mixture optionally contains a basic catalyst allowing the polymerization, chosen from LiOH, NaOH, KOH, M 2 CO 3 (M representing Li, Na, K, Cs and 0.5Mg)
- the synthetic mixture intended for the manufacture of hybrid peptide-silicic antibiotic, antimicrobial and / or antifungal materials as above is characterized in that the said synthetic mixture optionally contains a MF-type catalyst for the polymerization wherein M is Li, Na, K, Cs and a quaternary amine substituted with one or more groups identical to or different from each other selected from Me, Et, Pr, Pr, Bu and 3 ⁇ 4u.
- M is Li, Na, K, Cs and a quaternary amine substituted with one or more groups identical to or different from each other selected from Me, Et, Pr, Pr, Bu and 3 ⁇ 4u.
- FIG. 2 mass spectrum of the LC peak of FIG. 1 obtained at 0.76
- the peptide is synthesized on a solid support using a CEM Liberty TM peptide synthesizer using microwave irradiation at 2450 MHz for the Fmoc / tert-butyl strategy coupling and deprotection steps.
- the synthesis was carried out on a scale of 0.25 mmol on Fmoc-Rink-amide polystyrene resin (390 mg, 0.640 mmol / g) at a scale of 0.25 mmol.
- the coupling reactions are carried out with an excess of 5 equivalents of amino acid (0.2M stock solution in DMF), 5 equiv. HBTU (0.5M stock solution in DMF), and 10 equiv. of DIEA (2M stock solution in the NMP solution).
- the cleavage of the resin is carried out for 90 minutes with stirring in trifluoroacetic acid. After evaporation of the solvent and trituration with ether, the peptide in the form of TFA (TFA, H-Gly-Phe-Glu-NH 2 ) salts is solubilized in 20 ml of a water / acetonitrile mixture, frozen and then freeze-dried. .
- This functionalization pathway involves the grafting of hybrid elementary blocks in the pores of mesostructured silicas by reaction of these blocks with the silanol groups present on the surface of the pores.
- This functionalization pathway in the pores of mesostructured silicas consists of the co-hydrolysis-polycondensation of a hybrid elementary blocks and of tetraalkoxysilane in the presence of surfactant.
- Fluorescent nanoparticles are prepared according to:
- Hybrid peptides ( II ) Si (OEt) 3 (CH 2 ) 3 NHCO-pAla 4 [NP] and hybrid peptides (2) Si (OEt) 3 (CH 2 ) 3 NHCO-PAla 5 c [RGD]) [ Lii] are first synthesized by Solid Phase Peptide Synthesis (SSPS) by the "Fmoc" strategy on trityl resin, then is carried out in solution the derivation with. trietfa.oxysilylpropyiisocyan.ate:
- the functional Sinds are prepared according to the following method:
- the mixture is heated at 65 ° C for 12 hours.
- the completion of the reaction was monitored by RP-HPLC, verifying the disappearance of the hybrid peptides.
- the mixture is cooled to room temperature and centrifuged at 3000 rpm. It is washed once with DMF and twice with dichloromethane and the product obtained is dried under vacuum for 12 hours.
- a colloidal solution based on a mixture of bis-silylated polyethylene glycol (PEG1000) and the test hybrid peptide coxysilyl (in this case the antimicrobial sequence Si (OEt) 3 (CH 2 ) 3 NHCO-Ahx-Arg (Pbf) -ATg (Pbf) -NH2) acid ethanol is prepared and poured into a petri dish under controlled relative humidity.
- the evaporation of the solvent causes the process of the mineral polymerization to form a three-dimensional network in the form of a flexible membrane.
- the membrane thus obtained is endowed with property carried by the bioactive peptide.
- this type of structure requires a 24-mer peptide linked to a lipid tail and a beta sheet forming a sequence to induce and maintain the triple helix-type tropocollagen assembly.
- the use of much shorter hybrid peptides (9 amino acids) has allowed the formation of irreversibly fixed triple helices, This gives a block which forms a hollow tube.
- TEM microscopy images show very regular tubes with diameters of 14 nm and a wall thickness of 3.5 nm. This type of matrix could be used as a coating at the cellular level imitation of implantable bonding.
- the synthesis of the hybrid peptides of collagen was carried out on a solid support using a "rink" amide resin and a Fmoc / tBu strategy.
- the trialkoxysilyl spacer fragment was grafted onto the side chain of the N-terminal lysine.
- hybrid hollow silica-peptide tubes were prepared by the method of injecting a colloidal solution of ethanol into water.
- the hydrolysis of trialkoxysilane in the hybrid peptides was carried out in a solution of ethanol acid (pH 4) at room temperature for one hour.
- the resulting sol is then injected into a solution of H 2 0 / EtOH (90/10) (pH 4, at room temperature) to a final concentration of 0.5 rng.ml 1 and incubated at 45 ° C for 24 h.
- H 2 0 / EtOH 90/10
- the polymerization of a tripeptide (Gly-Phe-Arg) sequence is presented to produce comb-like polymers based on a bis-silylated lysine scaffold with branched peptide sequences.
- the first step is the synthesis of the hybrid peptide having lysine at its N-terminus which is functionalized with isocyanatopropyldimethylchlorosilane.
- isocyanatopropyldimethylchlorosilane only one hydrolyzable function is present on each silicon atom.
- each function can react once, resulting in uncrosslinked, i.e. linear, polymers.
- hybrid peptide [OHMe 2 Si- (CH 2 ) 3 NHC0 2 Lys] -Phe-Giy-Arg-NH 2 is carried out according to a conventional SPPS Fmoc / tBu strategy, followed by a derivatization isat ion. on resin free friend groups ⁇ and a N-terminal lysine by isocyanatopropyl dimethylchlorosilyl. After cleavage, the hybrid peptide is obtained as a dimethylsiloxane derivative. Such a hybrid peptide may be characterized by LC / MS.
- the intermolecular cyclized hybrid peptide is detected (m / z 806) by ESI + LC / MS. This species is in equilibrium with the linear hybri.de peptide (m / z 824).
- comb-shaped silicon peptide polymers can be obtained using the same strategy as described in Example 8, without the need for lysine derivative. .
- the hybrid peptide [(OH) 2 MeSi- (CH 2 ) 3 NHCO] 2 -A.hx-Arg (Pbf) -Arg (Pbf> NH 2 was prepared in solution during the reaction with dichloro- (3- isocyanatopropyl) (methyl) silane and the protected peptide H-Ahx-Arg (Pbf) -Arg (Pbf) -NH 2.
- dichloro- (3- isocyanatopropyl) (methyl) silane and the protected peptide H-Ahx-Arg (Pbf) -Arg (Pbf) -NH 2.
- the sylil dichloromethyl derivative two hydrolysable functions are present on each silicon atom.
- each function one on each hybrid peptide
- the LC / MS indicates the presence of dimer and tri-mother testifying the beginning of the polymerization process, even in a water / acetonitrile TF A in proportion of 1/1 / 0.001.
- the Ahx-Arg-Arg sequence is known to have antibiotic properties.
- the H-Ahx-Arg (Pbf) -Arg (Pbf) -] SIH 2 sequence was prepared on "Sieber amide" resin.
- the trialkyloxysilyl group was grafted onto the terminal amine of the directly cleaved peptide of the resin, without purification thereof, with 3-isocyanatopropyltriethoxysilane (ICPTS).
- ICPTS is soluble in diethyl ether while the protected hybrid peptide is not, which has facilitated recovery of the desired product at the 100 mg scale.
- the density of peptides on the surface was estimated at 1.35 peptide per nm 2 by a spectrophotometric technique based on the reversible complexation of Coomassie brilliant bkeu dye with guanidine groups.
- the plates of the functionalized glasses were incubated in petri dishes at 37 ° C. in the presence of a suspension. of. Coli in exponential phase of growth. These plates were washed and covered with bromide of ethydium prior to microscopic examination. A control sample (glass plate not treated with the hybrid peptide, but covered with TEOS) was incubated and treated under the same conditions. The comparison shows that numerous colonies are present on the glass plate without hybrid peptide, while the plate which comprises the peptide has none.
- the Boc-Pro-Pro-Asp-Lys-NH 2 sequence is known to have catalysis properties in the aldol reaction.
- the sequence H-Pro-Pro-Asp (OtBu) -Lys-NH 2 was prepared on 2-chloro chlorotrityl resin ( "CT"), starting the synthesis by the anchoring of a lysine (Fmoc-I .ys- NH ..) by its side chain to the resin.
- CT 2-chloro chlorotrityl resin
- the synthesis of the peptide sequence is carried out by conventional coupling techniques on solid support.
- the peptide was removed from the resin by gentle cleavage.
- the trialkyoxysilyl group was grafted onto the free amine ⁇ of the lysine residue thus liberated, directly cleaved from the resin, without purification of the latter, with 3-isocyanatopropyltriethoxysilane (ICPTS).
- ICPTS is soluble in diethyl ether while the protected hybrid peptide is not, which has facilitated recovery of the desired product at the 100 mg scale.
- a yield of about 60-70% was obtained for a degree of purity higher than 95%.
- Mesoporous silica with controlled pore diameters was prepared by co-hydrolysis and polycondensation of TEOS with the previously synthesized hybrid peptide. (99.8 / 0.2 mol / mol) in the presence of Pluronic P123® (PEO20POP70PEO20) as surfactant.
- Pluronic P123® PEO20POP70PEO20
- the hybrid material was quantitatively obtained after the surfactant was removed by washing.
- the resulting white powder was treated with HMD S and TFA to remove the terbutyl and Boc groups.
- the HMDS made it possible to hydrophobize the surface of the obtained material as water is not recommended for the aldolization reaction.
- the mesoporous silica obtained has an ordered structure SBA-15® by the so-called XRD technique and by N 2 adsorption-desorption measurement.
- SBA-15® by direct comparison with a "conventional" mesoporous silica SBA-15®, the effective pore size obtained is not particularly different.
- the HMDS treatment decreases the surface area by 25% and 17% of the pore volume, which is ultimately still within an acceptable range in perspective of a conventional SBA-15® silica.
- the mesoporous silica obtained above was used as a supported catalyst (2 mol%) for enantioselective alkylation in the reaction of p-nitrobenzaldehyde with acetone. The reactions were followed by HPLC. No reaction was recorded for the conventional SBA-15 ⁇ mesoporous silica. The mesoporous silica functionalized with the protected peptide also provided a negative test result. In.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Inorganic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Environmental Sciences (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Agronomy & Crop Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Polymers & Plastics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1255962A FR2992318B1 (en) | 2012-06-22 | 2012-06-22 | PEPTIDE-SILICE HYBRID MATERIALS |
PCT/EP2013/063171 WO2013190148A1 (en) | 2012-06-22 | 2013-06-24 | Peptide-silica hybrid materials |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2864340A1 true EP2864340A1 (en) | 2015-04-29 |
Family
ID=46852206
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13730896.1A Withdrawn EP2864340A1 (en) | 2012-06-22 | 2013-06-24 | Peptide-silica hybrid materials |
Country Status (4)
Country | Link |
---|---|
US (1) | US20160096865A1 (en) |
EP (1) | EP2864340A1 (en) |
FR (1) | FR2992318B1 (en) |
WO (1) | WO2013190148A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2463181B (en) | 2007-05-14 | 2013-03-27 | Univ New York State Res Found | Induction of a physiological dispersion response in bacterial cells in a biofilm |
FR3038609B1 (en) * | 2015-07-10 | 2020-03-06 | Centre National De La Recherche Scientifique (Cnrs) | NOVEL HYDROGELS WITH SILYLE STRUCTURE AND PROCESS FOR OBTAINING |
FR3038734A1 (en) | 2015-07-10 | 2017-01-13 | Centre Nat De La Rech Scient (Cnrs) | NEW FUNCTIONALIZED OPTICAL MATERIALS |
US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
FR3099060B1 (en) * | 2019-07-26 | 2022-01-14 | Bionuclei | MINERAL AND ORGANIC HYBRID COMPLEX AND ITS USE FOR MAINTAINING THE MICROBIOLOGICAL BALANCE OF THE SKIN AND/OR OF A COSMETIC AND/OR DERMOPHARMACEUTICAL COMPOSITION |
CN114748692B (en) * | 2022-03-11 | 2023-06-20 | 华南理工大学 | Mesoporous silica-based surface-functionalized titanium-based implant, and preparation method and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0540357A2 (en) * | 1991-11-01 | 1993-05-05 | CRODA INTERNATIONAL plc | Protein-silicone copolymers and compositions containing them |
US6358501B1 (en) * | 1998-10-17 | 2002-03-19 | Goldschmidt Gmbh | Polypeptide-polysiloxane copolymers |
GB2410896A (en) * | 2002-03-14 | 2005-08-17 | Croda Int Plc | Use of protein-silane/siloxane copolymers for reducing damage to hair caused by flexure and/or abrasion thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6476191B1 (en) * | 1999-02-05 | 2002-11-05 | Mixture Sciences, Inc. | Volatilizable solid phase supports for compound synthesis |
US9567353B2 (en) * | 2006-09-08 | 2017-02-14 | Cornell Research Foundation, Inc. | Sol-gel precursors and products thereof |
DE102008057684A1 (en) * | 2008-11-17 | 2010-05-20 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Dialkoxy- or dihydroxyphenyl radicals containing silanes, adhesives prepared therefrom and methods for preparing the silanes and the adhesives |
TW201114437A (en) * | 2009-10-20 | 2011-05-01 | Univ Nat Chiao Tung | Magnetic nanoparticles for magnetic resonace imaging |
-
2012
- 2012-06-22 FR FR1255962A patent/FR2992318B1/en not_active Expired - Fee Related
-
2013
- 2013-06-24 US US14/410,293 patent/US20160096865A1/en not_active Abandoned
- 2013-06-24 EP EP13730896.1A patent/EP2864340A1/en not_active Withdrawn
- 2013-06-24 WO PCT/EP2013/063171 patent/WO2013190148A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0540357A2 (en) * | 1991-11-01 | 1993-05-05 | CRODA INTERNATIONAL plc | Protein-silicone copolymers and compositions containing them |
US6358501B1 (en) * | 1998-10-17 | 2002-03-19 | Goldschmidt Gmbh | Polypeptide-polysiloxane copolymers |
GB2410896A (en) * | 2002-03-14 | 2005-08-17 | Croda Int Plc | Use of protein-silane/siloxane copolymers for reducing damage to hair caused by flexure and/or abrasion thereof |
Non-Patent Citations (4)
Title |
---|
DAVIS D H ET AL: "Immobilization of RGD to <111> silicon surfaces for enhanced cell adhesion and proliferation", BIOMATERIALS, ELSEVIER, AMSTERDAM, NL, vol. 23, no. 19, 1 October 2002 (2002-10-01), pages 4019 - 4027, XP004374395, ISSN: 0142-9612, DOI: 10.1016/S0142-9612(02)00152-7 * |
JONATHAN D. LUNN ET AL: "Peptide Brush-Ordered Mesoporous Silica Nanocomposite Materials", CHEMISTRY OF MATERIALS, vol. 21, no. 15, 11 August 2009 (2009-08-11), US, pages 3638 - 3648, XP055733938, ISSN: 0897-4756, DOI: 10.1021/cm901025n * |
KANIA C M ET AL: "Preparation of Poly(dimethylsiloxane)-Polypeptide Block Copolymers", JOURNAL OF APPLIED POLYMER SCIENCE, JOHN WILEY & SONS, INC, US, vol. 27, no. 1, 1 January 1982 (1982-01-01), pages 139 - 148, XP002167314, ISSN: 0021-8995, DOI: 10.1002/APP.1982.070270116 * |
See also references of WO2013190148A1 * |
Also Published As
Publication number | Publication date |
---|---|
FR2992318B1 (en) | 2018-11-16 |
FR2992318A1 (en) | 2013-12-27 |
US20160096865A1 (en) | 2016-04-07 |
WO2013190148A1 (en) | 2013-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2864340A1 (en) | Peptide-silica hybrid materials | |
ES2764252T3 (en) | Preparation procedure for high molecular weight oligo (alkylene glycol) functionalized polyisocyanopeptides | |
Liu et al. | Functionalization of polydopamine via the aza-michael reaction for antimicrobial interfaces | |
Godoy-Gallardo et al. | Antibacterial properties of hLf1–11 peptide onto titanium surfaces: A comparison study between silanization and surface initiated polymerization | |
Xu et al. | Twisted nanotubes formed from ultrashort amphiphilic peptide I3K and their templating for the fabrication of silica nanotubes | |
TWI465554B (en) | Novel lipid tripeptidic hydrogelling agent and hydrogel | |
JP4941845B2 (en) | Method for producing catechol-equivalent molecules useful for surface modification | |
TWI535832B (en) | Novel lipid dipeptide and gel | |
TWI491617B (en) | Novel lipid peptide and hydrogel | |
Kameta et al. | Soft nanotube hydrogels functioning as artificial chaperones | |
Yang et al. | Recent developments and applications of bioinspired dendritic polymers | |
Cao et al. | The impact of structure on elasticity, switchability, stability and functionality of an all-in-one carboxybetaine elastomer | |
Echalier et al. | Sol–gel synthesis of collagen-inspired peptide hydrogel | |
US20220127565A1 (en) | A Self-Assembling Short Amphiphilic Peptide And Related Methods And Uses | |
Appel et al. | Tuning the pH-triggered self-assembly of dendritic peptide amphiphiles using fluorinated side chains | |
EP3003968A1 (en) | Self-assembled micro- and nano-structures | |
WO2004003561A9 (en) | Peptide rod amphiphiles and self-assembly of same | |
Xie et al. | Recent progress in ionic coassembly of cationic peptides and anionic species | |
EP3320342B1 (en) | New hydrogels having a silylated structure, and method for obtaining same | |
Martin | Design and direct synthesis of peptide-branched polysiloxane. Towards new generation of hybrid biomaterials | |
WO2015181491A1 (en) | Method for grafting oligopeptides into porous hybrid materials | |
CN112442180B (en) | Amphiphilic polymer for promoting stem cell interface adhesion growth and preparation method and application thereof | |
Montheil et al. | Hybrid Silylated Peptides for the Design of Bio-functionalized Materials | |
Xin et al. | Oral Environment-Adaptive Peptide–Polymer Conjugate for Caries Prevention with Targeting, Antibacterial, and Antifouling Abilities | |
Cottenye | Antimicrobial surfaces based on self-assembled nanoreactors: from block copolymer synthesis to bacterial adhesion studies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20150121 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20180618 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: UNIVERSITE DE MONTPELLIER Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N. |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20210112 |